Interleukin-6 regulates androgen synthesis in prostate cancer cells Article (Faculty180)

cited authors

  • Chun, Jae Y; Nadiminty, Nagalakshmi; Dutt, Smitha; Lou, Wei; Yang, Joy C; Kung, Hsing- J; Evans, Christo P; Gao, Allen C


  • The standard systemic treatment for prostate cancer patients is androgen deprivation therapy. Although serum testosterone concentrations were significantly reduced after androgen deprivation therapy, levels of intraprostatic androgens are reproducibly measured at concentrations sufficient to activate androgen receptor and stimulate tumor growth, suggesting that prostate cancer cells may survive androgen deprivation therapies by increasing intracrine androgen synthesis within the prostate. However, factors that regulate de novo intracrine androgen synthesis have not been identified. Interleukin-6 (IL-6) has been implicated in the modulation of androgen receptor activation and growth and differentiation in prostate cancer. In this study, we investigate whether IL-6 regulates intraprostatic androgen synthesis in prostate cancer cells.

publication date

  • 2009

start page

  • 4815

end page

  • 22


  • 15